Drug intelligence / Profile preview

AGEX-iTR1547

Development stage: Discontinued
Lead developer: Serina Therapeutics
Modality: Small Molecules

Overview

**AGEX-iTR1547** is a proprietary drug-based formulation developed by AgeX Therapeutics using their induced Tissue Regeneration (iTR™) platform, currently in preclinical development. It aims to reverse age-related degenerative changes by restoring regenerative potential in aged tissues through reducing expression of the marker gene **COX7A1**, associated with loss of cellular regenerative capacity. The candidate targets applications in degenerative diseases, including cardiovascular conditions like heart failure and congestive heart failure, scarless wound repair, and potentially broader age-related tissue rejuvenation, with ongoing research to optimize it as a pharmaceutical preparation.[1][2][4][6][7][11][12][13][14][15]

Targets

COX7A1 (Cytochrome C Oxidase)

Beyond the preview

Go deeper on AGEX-iTR1547.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGEX-iTR1547.

Explore the full profile